Finally, as well as providing a new potential therapeutic approach for the treatment of PCa patients, since ERG rearrangements and fusions are also present in Ewing’s sarcoma44 and in acute myeloid leukaemia,45 and no doubt in other neoplasms, the use of SSOs to target ERG may be a suitable therapeutic approach in several cancer types. The gene discussed is ERG; the disease is acute myeloid leukemia.